TerminatedInterventionalPhase 1Phase 2Updated Dec 13, 2017
Prophylactic Quetiapine on Delirium Prevention in Critically Ill Patients | NCT02297763 | Trialant
Unknown statusInterventionalPhase 3Updated Nov 21, 2014
Prophylactic Quetiapine on Delirium Prevention in Critically Ill Patients
ClinicalTrials.gov ID
NCT02297763
Lead Sponsor
Seoul National University HospitalOTHER
Overall Status
Unknown status
Study Type
Interventional
Phase
Phase 3
Enrollment
194Estimated
Last Update Posted
Nov 21, 2014Estimated
Start Date
Mar 2015
Primary Completion Date
Sep 2016Estimated
Brief Summary
The purpose of this study is to evaluate the efficacy of low dose quetiapine for the prophylaxis of delirium in critically ill patients in medical intensive care unit.
Delirium
quetiapine
placebo
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Greater than or equal to 19 years of age, admitting to medical ICU, anticipated to stay more than 72hours
Exclusion Criteria:
Female patients who are pregnant or breastfeeding
active delirium
Received other anti-psychotic drug before attend the study